Dinesh Khanna
Clinical trials
Chemomab
Israel
Biography
Prof. Khanna is a Professor of Medicine and Director of the University of Michigan (UM) Scleroderma Program. UM Scleroderma Program is a tertiary referral center for patients with scleroderma and related conditions. The program sees approximately 1,200-1,500 unique patient visits on an annual basis and has 3 full-time faculty members and 5 coordinators. Prof. Khanna have expertise in developing/validating outcome measures for clinical trials and led the development of the Combined Response Index in Systemic Sclerosis (NIH/NIAMS funded effort), which is now included as primary, secondary, and exploratory measures in ongoing trials. Dr. Khanna’s research has focused on the development of outcome measures and refinement of trial design in scleroderma. Based on his expertise in trial design and outcome measures, he co-led the EULAR Points to Consider recommendations for trial design in SSc and will chair a project with the NIH and FDA colleagues to develop a white paper for clinical trials in SSc.
Research Interest
Clinical trials
